NEW YORK - SELLAS Life Sciences announced on November 17, 2026, that its immunotherapeutic cancer vaccine galinpepimut-S met the primary endpoint in the pivotal Phase 3 REGAL trial for acute myeloid leukemia. The maintenance monotherapy reduced the risk of death by 41% compared with best available treatment.
Survival Gains and Safety Profile in High-Risk Patients
Topline analysis triggered after 80 prespecified death events showed a substantial overall survival advantage over investigator-selected therapies. Treated patients achieved a median overall survival of 24.0 months versus 14.7 months in the control group, yielding a hazard ratio of 0.59 and a two-sided p-value of 0.035. "REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission," Chief Executive Angelos Stergiou said. No new safety signals emerged, with mild-to-moderate injection-site reactions most common.
FDA Meeting and 2027 BLA Filing Plans
The 126-patient global trial enrolled individuals in second or later remission who could not undergo allogeneic stem cell transplantation, validating SELLAS's WT1-targeted vaccine platform. SELLAS plans to meet with the United States Food and Drug Administration to discuss an accelerated filing strategy and prepare a Biologics License Application for submission in the first half of 2027. Secondary endpoint analyses remain underway for presentation at an upcoming medical conference.



